14,474 results found

In the August 10, 2015, Federal Register, Grain Inspection, Packers and Stockyards Administration ("GIPSA") announced an extension to the request for information period...

In the February 24, 2016, Federal Register, USDA's Grain Inspection, Packers and Stockyards Administration ("GIPSA") announced the extension of the comment period for its proposed rule addressing changes to the United States Grain Standards Act.

In the January 25, 2016, Federal Register, USDA's GIPSA proposed to revise existing regulations and add new regulations under the United States Grain Standards Act ("USGSA")...

The Advisory Committee meets twice annually to advise GIPSA on the programs and services it delivers under the U.S. Grain Standards Act.

In the June 12, 2017, Federal Register, USDA's Grain Inspection Packers and Stockyards Administration ("GIPSA") announced the suspension of fees charged for the supervision of official inspection...

Residents in both Oregon and Colorado voted against ballot initiatives that would have required labeling foods made with GMOs.

Earlier this month, Pryor Cashman client Greenlane Holdings, Inc., a leading distributor of premium vaporization products and consumption accessories, commenced an initial public offering of its Class A common stock.

On December 2, 2015, the Grocery Manufacturers Association ("GMA") announced an innovative technology, called SmartLabel...

Under the terms of the settlement, Monos will pay approximately $2 million to settle the state and federal claims against it.

On March 26, 2015, U.S. Department of Health & Human Services Secretary Sylvia M. Burwell announced a new initiative targeting prescription opioid-related overdose, death, and dependence.

The HHS Office of Disease Prevention and Health Promotion is soliciting public comment on the draft National Action Plan for Adverse Drug Event Prevention. The document focuses on the use of surveillance, prevention, incentives and oversight, and research to reduce adverse drug events.

On July 10, 2015, the House of Representatives passed on a 344-77 vote the 21st Century Cures Act, H.R. 6, legislation intended to improve the drug and device development processes and expedite patient access to medical treatments.

The U.S. House of Representatives has approved by voice vote H.R. 1919, Safeguarding America’s Pharmaceuticals Act of 2013. H.R. 1919 is a bipartisan bill intended to improve drug distribution security and protect against counterfeit pharmaceuticals.

On April 21, 2015, the House of Representatives approved H.R. 471, the Ensuring Patient Access and Effective Drug Enforcement Act of 2015.

On May 21, 2015, the House Energy & Commerce Committee voted unanimously to advance H.R. 6, the 21st Century Cures Act, which aims to accelerate the pace of innovative medical therapies through a variety of regulatory reforms...

On July 10, 2015, the U.S. House of Representatives approved H.R. 6, the 21st Century Cures Act ("Cures Act"), by a vote of 344–77, setting up the legislation for consideration in the U.S. Senate.

The U.S. House of Representatives has passed the SAFE Banking Act, which allows financial-service firms to work with "cannabis-related legitimate businesses and service providers,"